Agili-C™ Implant Performance Evaluation
Tab Title Description
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Rochester, Minnesota: 17-003562
NCT ID: NCT03299959
Sponsor Protocol Number: CLN0021
About this study
The current study compares the efficacy and safety of the Agili-C implant to Surgical Standard of Care treatment in patients suffering from joint surface lesions of the knee. The patient population is heterogeneous, involving different kinds of joint surface lesions: focal cartilage lesions, osteochondral defects and mild to moderate osteoarthritis, including multiple defects.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
- 21 -75 years
- Up to 3 treatable joint surface lesion(s), ICRS Grade III or above, on the femoral condyles and/or trochlea
- Symptomatic total treatable area 1-7 cm². Asymptomatic lesions will not be included in the calculation
- Must be physically and mentally willing and able to comply with the post-operative rehabilitation protocol and scheduled clinical and radiographic visits
- Signed and dated the IRB/Ethics Committee approved Informed Consent Form and HIPPA (if applicable)
- Non-responsive to physical therapy for at least 3-4 weeks
- KOOS Pain Subscale score at baseline is less than 20 or more than 65 (scale: maximum pain =0, pain free =100)
- Bony defect depth deeper than 8mm, according to baseline MRI/X-ray/arthroscopy
- Articular cartilage lesions in the tibia or the patella, ICRS grades IVa or above
- Osteoarthritis of the index knee graded 4 according to the Kellgren-Lawrence Grading
- Significant instability of the index knee according to IKDC Knee Examination Form 2000, Grade C (abnormal) or D (severely abnormal)
- Malalignment more than 8 degrees varus OR 8 degrees valgus according to standing X-ray
- Lack of functional remaining meniscus, at least 5mm rim at the end of the procedure
- Meniscal transplantation in the past 6 months
- Any known tumor of the index knee
- Any known history of intra-articular or osseous infection of the index knee
- Any evidence of active infection anywhere in the body. Urinary Tract Infection (UTI) patients can be included following antibiotic treatment, and provided that two consecutive cultures are negative (taken within at least 2 weeks of each other)
- Any known history of inflammatory arthropathy or crystal-deposition arthropathy
- Any known systemic cartilage and/or bone disorder, such as but not limited to, osteoporosis, chondrodysplasia or osteogenesis imperfecta
- Body Mass Index (BMI) > 35
- Chemotherapy in the past 12 months
- Any previous surgical cartilage treatment (such as: microfracture, ACI, OATS, etc.) in the index knee within the last 6 months
- Any previous ligamentous repair or malalignment correction in the index knee within the last 6 months
- History of allergic reaction or intolerance of materials containing calcium carbonate or hyaluronate
- Patient who is pregnant or intends to become pregnant during the study
- History of any significant systemic disease, such as but not limited to: HIV, hepatitis, HTLV, syphilis, and coagulopathies
- Known substance or alcohol abuse
- Participation in other clinical trials within 60 days prior to the study or concurrent with the study
- Known insulin dependent diabetes mellitus
- Unable to undergo either MRI or X-ray
- Use of anticoagulation medication or antiaggregant medication; however up to 100 mg Acetylsalicylic acid (ASA) daily is allowed
- Previous intra-articular steroid injection within the last 1 month
- Uncontained lesion - Lack of vital bone wall, at least 2mm thick, completely surrounding the lesion - based on MRI/X-ray/arthroscopy
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
|Mayo Clinic Location
Mayo Clinic principal investigator
Aaron Krych, M.D.
Closed for enrollment
Publications are currently not available